Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies
Open Access
- 15 November 2010
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (10) , 1492-1499
- https://doi.org/10.1086/656717
Abstract
CMX001, an orally active lipid conjugate of cidofovir, is 50 times more active in vitro against herpes simplex virus (HSV) replication than acyclovirKeywords
This publication has 40 references indexed in Scilit:
- Inhibition of Herpesvirus Replication by 5-Substituted 4′-Thiopyrimidine NucleosidesAntimicrobial Agents and Chemotherapy, 2009
- Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infectionAntiviral Research, 2009
- MRI Deterioration in Herpes Simplex Encephalitis Despite Clinical RecoveryThe Neurologist, 2009
- Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real‐time PCR in patients with herpes simplex encephalitisJournal of Medical Virology, 2009
- Synergistic Efficacy of the Combination of ST-246 with CMX001 against OrthopoxvirusesAntimicrobial Agents and Chemotherapy, 2007
- Diagnosis and treatment of viral encephalitisPostgraduate Medical Journal, 2002
- Herpes Simplex Virus Infections of the Central Nervous SystemDrugs, 1991
- Enhanced in vitro reactivation of latent herpes simplex virus from neural and peripheral tissues with hexamethylenebisacetamideArchiv für die gesamte Virusforschung, 1988
- Vidarabine versus Acyclovir Therapy in Herpes Simplex EncephalitisNew England Journal of Medicine, 1986
- Adenine Arabinoside Therapy of Biopsy-Proved Herpes Simplex EncephalitisNew England Journal of Medicine, 1977